Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levofloxacin + dexamethasone
- Development stage
- Phase 3
- Lead developer
- NTC Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
Levofloxacin + dexamethasone is a fixed-dose combination ophthalmic solution containing two active ingredients: levofloxacin, a fluoroquinolone antibiotic, and dexamethasone, a corticosteroid. This combination is primarily indicated for the prevention and treatment of inflammation and the prevention of infection associated with cataract surgery in adults. Levofloxacin acts by inhibiting bacterial DNA gyrase and bacterial topoisomerase IV, thereby preventing bacterial replication. Dexamethasone exerts its anti-inflammatory effects by binding to glucocorticoid receptor, suppressing inflammatory cytokines and mediators. The combination provides both potent anti-infective coverage against ocular pathogens and effective control of post-surgical inflammation[1][2][3][6]. It is administered as eye drops. Developers: SIFI Manufacturers: SIFI
- Brand names
- LevodexaDucressa
- Other names
- dexamethasone/levofloxacinlevofloxacin/dexamethasone
02
Targets
GR (Glucocorticoid receptor)Topo IV (Bacterial Topoisomerase IV)DNA gyrase
Beyond the preview
Go deeper on levofloxacin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levofloxacin + dexamethasone.